AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 61 min read$IRTC

Turakhia Minang sold $177K of IRTC

Turakhia Minang (CHIEF MED/SCI OFCR EVP ADVTECH) sold 1,423 shares of iRhythm Holdings, Inc. (IRTC) at $124.71 ($0.18M total) on 2026-07-02.

Original reporting
SEC EDGAR · Turakhia Minang
Published Jul 6, 2026, 8:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 6, 2026, 8:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$IRTC
Neutral
medium confidence
Mentioned
$IRTC
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRTCNeutralLow
01

Why it matters

The disclosure updates insider ownership/transaction history but does not introduce new information about iRhythm’s business performance or outlook.

02

Market read

Traders may monitor for follow-on insider selling, but this single Form 4 does not provide a fundamental catalyst.

03

What to watch

Insider sales can be driven by diversification, taxes, or personal liquidity needs; the article lacks context on total insider activity, compensation, or prior sales cadence.

Relevance 4/10Novelty 3/10Timing: Filed 2026-07-06 after-hours; reflects sale executed 2026-07-02.

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for iRhythm Holdings, Inc.

Company-level read

Ticker impact

$IRTCNeutralMedium confidence
Context

Turakhia Minang, iRhythm’s EVP/Chief Med/Science Officer, filed an open-market sale of 1,423 shares at $124.71 on 2026-07-02.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-only and typically fades unless accompanied by broader insider selling or new fundamentals.

Evidence & confidence

The filing provides transaction size, price, and post-sale holdings, but no earnings, guidance, regulatory, or operational catalyst. Insider sales are common and often not predictive without additional context.

Market effects

Sector

No clear sector read-through; this is company-specific insider activity without operational or regulatory linkage.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale was not under a pre-arranged 10b5-1 plan (per the filing), some traders may interpret it as higher near-term risk—though the article provides no reason for the sale.

Key entities

  • issuer
    iRhythm Holdings, Inc.

    Subject of the Form 4 insider transaction disclosure (IRTC).

  • insider
    Turakhia Minang

    Chief Med/SCI Officer, EVP AdvTech; reported an open-market sale of 1,423 shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

IRTC insider trading history →

Related articles

OCT 5
$IRTCMedAI 8/10

iRhythm completes acquisition of VitalConnect

iRhythm (IRTC) completed its acquisition of VitalConnect for $237.5M in cash and up to 423,334 shares. The deal includes a $10M working capital funding. VitalConnect's cardiac monitoring platform offers 30-day patient monitoring and 11 physiological parameters. iRhythm expects enhanced revenue growth from 2027, maintaining a 15% adjusted EBITDA margin target. Updated 2026 guidance will be provided in November 2026.

investing.com2 min
OCT 5
$IRTCMedAI 9/10

Transaction Detail The purchase consideration consisted of $237.5 million in cash, subject to customary adjustments, funded from iRhythm's balance sheet and…

iRhythm Holdings, Inc. (IRTC) filed an SEC Form 8-K — Regulation FD Disclosure. iRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care  Combination broadens iRhythm’s cardiac monitoring portfolio, advances its multi-vitals strategy and expands iRhythm’s addressable mark

SEC EDGAR 8-K2 min
OCT 5
$IRTCHighAI 9/10

iRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care

iRhythm (IRTC) completed its acquisition of VitalConnect, a leader in wearable biosensor and ambulatory cardiac monitoring technology. The $237.5M cash deal, plus up to 423,334 shares, is expected to expand iRhythm's cardiac monitoring portfolio, accelerate growth, and preserve its 15% adjusted EBITDA margin target for 2027. The combined entity aims to serve more patients and customers across various care settings.

globenewswire.com3 min
SEP 22
$IRTCMedAI 8/10

IRhythm Holdings, Inc., a Delaware corporation, iRhythm Technologies, Inc., a Delaware corporation and a direct wholly owned subsidiary of the Company…

iRhythm Holdings, Inc. (IRTC) filed an SEC Form 8-K — Regulation FD Disclosure. Item 7.01. Regulation FD Disclosure. As previously announced, on August 5, 2026, iRhythm Holdings, Inc., a Delaware corporation (the “Company”), iRhythm Technologies, Inc., a Delaware corporation and a direct wholly owned subsidiary of the Company (“Acquirer”), Project Vessel Mer

SEC EDGAR 8-K1 min